{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:42:23Z","timestamp":1780098143405,"version":"3.54.0"},"reference-count":42,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.3892\/ol.2016.5530","type":"journal-article","created":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T12:12:18Z","timestamp":1482495138000},"page":"1425-1431","source":"Crossref","is-referenced-by-count":11,"title":["Dinitrophenyl hapten with laser immunotherapy for advanced malignant melanoma: A clinical study"],"prefix":"10.3892","volume":"13","author":[{"given":"Dian-Jun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-Rong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Fang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-Huan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-R","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2016,12,23]]},"reference":[{"key":"key20180108112418_b1-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1365-2133.2002.04867.x","article-title":"Metastatic pathways and time courses in the orderly progression of cutaneous melanoma","volume":"147","author":"Meier","year":"2002","journal-title":"Br J Dermatol"},{"key":"key20180108112418_b2-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1046\/j.1365-2230.2000.00690.x","article-title":"Classical chemotherapy for metastatic melanoma","volume":"25","author":"Becker","year":"2000","journal-title":"Clin Exp Dermatol"},{"key":"key20180108112418_b3-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejca.2009.10.032","article-title":"Diagnosis and treatment of melanoma: European consensus based interdisciplinary guideline","volume":"46","author":"Garbe","year":"2010","journal-title":"Eur J Cancer"},{"key":"key20180108112418_b4-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1200\/JCO.1998.16.5.1752","article-title":"Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma","volume":"16","author":"Legha","year":"1998","journal-title":"J Clin Oncol"},{"key":"key20180108112418_b5-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1200\/JCO.1999.17.9.2752","article-title":"Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor and tamoxifen for patients with metastatic melanoma","volume":"17","author":"O'Day","year":"1999","journal-title":"J Clin Oncol"},{"key":"key20180108112418_b6-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"key20180108112418_b7-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00001622-199703000-00016","article-title":"The treatment of metastatic melanoma with chemotherapy and biologics","volume":"9","author":"Atkins","year":"1997","journal-title":"Curr Opin Oncol"},{"key":"key20180108112418_b8-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/1097-0142(19900601)65:11<2478::AID-CNCR2820651114>3.0.CO;2-S","article-title":"A phase II trial of taxol in metastatic melanoma","volume":"65","author":"Legha","year":"1990","journal-title":"Cancer"},{"key":"key20180108112418_b9-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.1995.13.12.2895","article-title":"Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy","volume":"13","author":"Bedikian","year":"1995","journal-title":"J Clin Oncol"},{"key":"key20180108112418_b10-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2004.04.165","article-title":"Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study","volume":"22","author":"Avril","year":"2004","journal-title":"J Clin Oncol"},{"key":"key20180108112418_b11-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.4161\/hv.20923","article-title":"A tale of two pities: Autologous melanoma vaccines on the brink","volume":"8","author":"Berd","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"key20180108112418_b12-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJM197202242860804","article-title":"A method for dinifrochlorobengene contact sensitigafron: A clinico pathological study","volume":"286","author":"Calalona","year":"1972","journal-title":"N Engl J Med"},{"key":"key20180108112418_b13-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1600-0625.2008.00802.x","article-title":"The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells","volume":"18","author":"Fujisawa","year":"2009","journal-title":"Exp Dermatol"},{"key":"key20180108112418_b14-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.coi.2004.01.010","article-title":"Immunoregulatory T cells in tumor immunity","volume":"16","author":"Terabe","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"key20180108112418_b15-ol-0-0-5530","first-page":"5267","article-title":"Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+\/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta","volume":"62","author":"Somasundaram","year":"2002","journal-title":"Cancer Res"},{"key":"key20180108112418_b16-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S1470-2045(11)70155-3","article-title":"Regulatory T cells in melanoma: The final hurdle towards effective immunotherapy?","volume":"13","author":"Jacobs","year":"2012","journal-title":"Lancet Oncol"},{"key":"key20180108112418_b17-ol-0-0-5530","first-page":"606","article-title":"Increase of regulatory T cell in the peripheral blood of cancer patients","volume":"9","author":"Wolf","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key20180108112418_b18-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1084\/jem.192.2.295","article-title":"Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation","volume":"192","author":"Read","year":"2000","journal-title":"J Exp Med"},{"key":"key20180108112418_b19-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1111\/j.1600-0625.2009.01055.x","article-title":"Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination","volume":"19","author":"Correll","year":"2010","journal-title":"Exp Dermatol"},{"key":"key20180108112418_b20-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12253-010-9254-x","article-title":"FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma","volume":"16","author":"Lad\u00e1nyi","year":"2010","journal-title":"Pathol Oncol Res"},{"key":"key20180108112418_b21-ol-0-0-5530","first-page":"223","article-title":"Infiltrative T regulatory cells in enucleated uveal melanomas","volume":"107","author":"Lagouros","year":"2009","journal-title":"Trans Am Ophthalmol Soc"},{"key":"key20180108112418_b22-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/cncr.24999","article-title":"Intratumoral forkhead boxP3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma","volume":"116","author":"Mougiakakos","year":"2010","journal-title":"Cancer"},{"key":"key20180108112418_b23-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2133.2007.08057.x","article-title":"Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases","volume":"157","author":"Mourmouras","year":"2007","journal-title":"Br J Dermatol"},{"key":"key20180108112418_b24-ol-0-0-5530","volume-title":"AJCC cancer staging handbook: From the AJCC cancer staging manual","author":"Edge","year":"2010"},{"key":"key20180108112418_b25-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L","article-title":"The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma","volume":"1","author":"Karnofsky","year":"1948","journal-title":"Cancer"},{"key":"key20180108112418_b26-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20180108112418_b27-ol-0-0-5530","journal-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0."},{"key":"key20180108112418_b28-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s001050050695","article-title":"Immune chemotherapy of malignant melanoma. Epifocal administration of dinitrochlorobenzene (DNCB) combined with systemic chemotherapy with dacarbazine (DTIC)","volume":"49","author":"Trcka","year":"1998","journal-title":"Hautarzt"},{"key":"key20180108112418_b29-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJM197202242860804","article-title":"A method for dinitrochlorobenzene contact sensitization. A clinicopathological study","volume":"286","author":"Calalona","year":"1972","journal-title":"N Engl J Med"},{"key":"key20180108112418_b30-ol-0-0-5530","first-page":"193","article-title":"Prognostic factors in 1,521 melanoma patients with distant metastasis","volume":"181","author":"Barth","year":"1995","journal-title":"J Am Coll Surg"},{"key":"key20180108112418_b31-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1109\/JSTQE.2011.2182183","article-title":"Laser immunotherapy: Concept, possible mechanism, clinical applications and recent experimental results","volume":"18","author":"Li","year":"2012","journal-title":"IEEE J Selected Topics Quantum Electronics"},{"key":"key20180108112418_b32-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.4161\/cbt.10.11.13434","article-title":"Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: A preliminary study","volume":"10","author":"Li","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"key20180108112418_b33-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/1534735410387597","article-title":"Long-term effect on EMT6 tumors in mice induced by combination of laser immunotherapy and surgery","volume":"10","author":"Li","year":"2011","journal-title":"Integrative Cancer Ther"},{"key":"key20180108112418_b34-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00432-006-0182-9","article-title":"Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: Results of a nationwide survey of the German Dermatologic Co-operative Oncology Group","volume":"133","author":"Terheyden","year":"2007","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20180108112418_b35-ol-0-0-5530","first-page":"722","article-title":"Vaccinal cell therapy in melanoma","volume":"90","author":"Quillien","year":"2003","journal-title":"Bull Cancer"},{"key":"key20180108112418_b36-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s00262-002-0285-3","article-title":"Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses","volume":"51","author":"Berd","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"key20180108112418_b37-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/CMR.0b013e32834b58fa","article-title":"Dendritic cell-based vaccine in advanced melanoma: Update of clinical outcome","volume":"21","author":"Ridolfi","year":"2011","journal-title":"Melanoma Res"},{"key":"key20180108112418_b38-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijrobp.2012.03.017","article-title":"The abscopal effect associated with a systemic anti-melanoma immune response","volume":"85","author":"Stamell","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20180108112418_b39-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00262-002-0292-4","article-title":"Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response","volume":"51","author":"Wack","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"key20180108112418_b40-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nbt0102-64","article-title":"Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine","volume":"20","author":"Kumamoto","year":"2002","journal-title":"Nat Biotechnol"},{"key":"key20180108112418_b41-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00262-011-1019-1","article-title":"Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine","volume":"60","author":"Mahipal","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"key20180108112418_b42-ol-0-0-5530","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2016.5530\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T11:13:50Z","timestamp":1718968430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2016.5530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,23]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,12,23]]},"published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.3892\/ol.2016.5530"],"URL":"https:\/\/doi.org\/10.3892\/ol.2016.5530","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,23]]}}}